Navigation Links
Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
Date:10/26/2007

SAN FRANCISCO, Oct. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2007 AACR-NCI- EORTC International Conference in San Francisco that its integrin-targeted PI3 kinase inhibitor, SF1126, showed synergistic effects with certain standard chemotherapy agents in vitro and in vivo (poster C207).

In vitro data showed significant (p<0.001) synergistic growth inhibition of prostate cancer cells with combinations of docetaxel and SF1126, as well as synergistic growth inhibition of brain cancer cells with combinations of doxorubicin and SF1126. In addition, SF1126 and rapamycin showed excellent growth inhibition synergies across all prostate, renal and non-small cell lung cancer cell lines. Simultaneous dosing of SF1126 with docetaxel in a prostate xenograft model exhibited slightly improved tumor response time versus administering SF1126 prior to docetaxel administration. In this same xenograft model, using very large tumors, it was shown that SF1126 in combination with docetaxel gave significantly greater tumor regression than did docetaxel alone (p<0.05). SF1126 as a single agent showed significant tumor growth inhibition relative to the control group (73% inhibition, p<0.01) in this model as well.

"These data support that our lead compound, SF1126, is active as a single agent and in synergy with a growing list of standard chemotherapy agents," said Edward Jacobs, Semafore's president and chief executive officer. "This provides us with a pathway to clinical development in addition to our current phase I clinical trial in patients with solid tumors. We expect to complete our phase I clinical trial in the second quarter of 2008 and then evaluate SF1126 in additional trials, both as a single and combined therapy."

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
5. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
9. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
10. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
11. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., MINNEAPOLIS, Nov. 20 ...results for its first quarter ended September 30, ...iluted share, on revenues of $3,263,000. This com...luted share, on revenues of $3,168,000 for the fir...irst quarter results, Biotel President and CEO Ste...
(Date:11/20/2009)..., FRANKLIN LAKES, N.J., Nov. 20 /PRNewswire-Fir...E: BDX ) today announced the completion of its a...an-based company that develops and manufactures mo.... ,, In May 2009, BD and HandyLab announced an ...alize molecular assays on the HandyLab Jaguar(TM) ...
(Date:11/19/2009)... , ARDEE, Ireland, Nov. 19 Warn...he pricing of its previously announced secondary o...price to the public of $22.25 per share. The sell...n Capital Partners, DLJ Merchant Banking, J.P. Mor...H. Lee Partners, L.P., certain other institutional...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Growing Supply Chain Complexity Increasing Impact on Medical Device Company Operations 5442 1Growing Supply Chain Complexity Increasing Impact on Medical Device Company Operations 5442 2Growing Supply Chain Complexity Increasing Impact on Medical Device Company Operations 5442 3BIOSAFE Launching In a New Specially Treated Facemask Effective Against H1N1 Influenza 5438 1BIOSAFE Launching In a New Specially Treated Facemask Effective Against H1N1 Influenza 5438 2BIOSAFE Launching In a New Specially Treated Facemask Effective Against H1N1 Influenza 5438 3BIOSAFE Launching In a New Specially Treated Facemask Effective Against H1N1 Influenza 5438 4Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR 28R 29 5434 1Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR 28R 29 5434 2Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR 28R 29 5434 3
...CO, Calif., March 26 Poniard,Pharmaceuticals, Inc...cused,on oncology, announced an agreement with W. ... supply of picoplatin active pharmaceutical,ingred...he Company,s lead,product candidate, in four clini...trial in small cell lung cancer, and is developing...
...ts collaborate with UBC to provide best science av...s cutting-edge,thinking in study methodology for C...UBC) announces the formation of a European Advisor...established to support UBC in its,ongoing efforts ... that,rely on subjective measurements as pivotal e...
Other Medicine Technology:Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin 2Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin 3UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 2UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 3
(Date:11/21/2009)... Group ask whether there is a secret to ,alcohol r... London, UK (PRWEB) November 21, 200...hree of the adult UK population drinking enough al...ed liver disease*, it is hardly a surprise that ma...rammes and residential centres for help. However, ...
(Date:11/20/2009)... The American Academy o... care reform legislation released this week to con...e individual coverage mandate. The actuaries said ...imize adverse selection stemming from more restric.... ,, "The individual mandate language should be...
(Date:11/20/2009)...s and Congressmen in Competitive Re-election Battl... , Washington, DC (Vocus)...ning for re-election next year in races deemed to ... come to regret voting for House Speaker Nancy Pel...ing Zogby International/ O’Leary Report pol...
(Date:11/20/2009)... Centene Corporation (N...at the Bank of America Merrill Lynch 2009 Credit C...rowne Plaza Hotel Times Square in New York City. ,...at 8:30 a.m. Eastern Time. Investors and other int...f Centene,s presentation at: http://www.veracast....
(Date:11/20/2009)...ewswire-USNewswire/ -- The following is a statemen...da Health Care Association: ,, "The Nevada Heal...ate Majority Leader Harry Reid for his leadership ... of protecting every Nevada seniors, ongoing acces... strength and viability of our state,s vital front...
Breaking Medicine News(10 mins):Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Just 25% of Voters in Competitive 2010 Senate Races &#8220;Much More Likely&#8221; to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races &#8220;Much More Likely&#8221; to Support Pelosi-Democrats Who Voted for Health Care Bill 3
...egina is a volunteer of Médecins sans Frontières (... patients in the area take their medication regula...sease. The chief difficulty // for those who are ...a patient has to consume. Volunteers help t...
...mericans consume far too much sodium, putting them...d stroke, according to a new study published in th...ive Medicine. // Although people who already... levels, according to lead researcher Umed Ajani, ...
...r Adam Gibson and his research team are all set to...IR). This brain scanner provides an insight ab... it etc. // It was developed by University College...xecute brain scans on babies. One is the usage o...
...esearchers at the Bassett Research Institute of th...w York and The Thomas Jefferson University in Phil...cancer in laboratory mice was // stimulated by the...th Sciences, also found that the tumors were stimu...
...f smoking were to be banned by the Government in b...e will be affected by passive smoking. Children su...ficulties due to passive smoking. The economists b...o quit as a result of a total ban, according to th...
...he risk of a degenerative eye disease is raised du...of the eye degenerates with higher levels of smoki...ading which require fine central vision. About 435...s the amount smoked rather than whether someone ha...
Other Medicine News:Health News:Americans Consume Far Too Much Salt and Sodium 2Health News:Detecting Brain Abnormalities in Babies Using New Brain Scanners. 2Health News:Artificial Light Stimulates Breast Cancer Growth In Mice: Study 2
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
Medicine Products: